Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group
Authors:
- 20 May 2019
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 66 (8) , e27812
Abstract
Background: Approximately one‐third of children with acute myeloid leukemia (AML) relapse, requiring re‐treatment and allogeneic hematopoietic stem cell transplantation (HSCT). Although achieving second complete remission (CR2) prior to HSCT is desirable, once CR2 is attained, it is unclear if there is any benefit from further chemotherapy prior to HSCT. Moreover, although pre‐HSCT minimal residual disease (MRD) has prognostic value in acute lymphoblastic leukemia, the benefit of MRD reduction after achieving CR prior to HSCT is less clear for AML.Procedure: To address these questions, we analyzed data from pediatric transplant centers in Australia and New Zealand concerning relapsed childhood AML cases occurring between 1998 and 2013. Given the retrospective nature of our analysis and assay data available, we analyzed patients on the basis of measurable residual disease (MeRD) by any methodology, rather than MRD in the conventional sense.Results: We observed improved overall survival (OS) in children receiving two chemotherapy cycles, compared to one cycle or three or more cycles pre‐HSCT. Improved OS with two cycles remained significant for patients without MeRD after cycle 1.Conclusions: These data suggest that a second chemotherapy cycle pre‐HSCT may improve survival by lowering disease burden. Prospective trials assessing strategies to reduce pre‐HSCT MRD in relapsed childhood AML are warranted.Keywords
This publication has 15 references indexed in Scilit:
- A Review of Hematopoietic Cell Transplantation in Australia and New Zealand, 2005 to 2013Transplantation and Cellular Therapy, 2016
- Collaborative Efforts Driving Progress in Pediatric Acute Myeloid LeukemiaJournal of Clinical Oncology, 2015
- The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997–2008: A report from the Australian Paediatric Cancer RegistryPediatric Blood & Cancer, 2015
- Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and futureBone Marrow Transplantation, 2014
- Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remissionBlood, 2013
- Novel therapies for children with acute myeloid leukaemiaLeukemia, 2013
- Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology GroupBlood, 2012
- Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemiaBlood, 2012
- Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A therapeutic advances in childhood leukemia (TACL) consortium studyPediatric Blood & Cancer, 2010
- Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study GroupBlood, 2002